Eureka report has a really good article on it recommending an out perform...
The key things i like and take from the report are: - outperform - valuation 0.39 - 25% annual rev growth projection - growth to be limited by supply constraints not demand (what a lovely problem to have) -high conversion of NPAT to Free Cash Flow - Net Cash - Industry growth of net 20% -So an out perform of 5% on an industry growth of 20% seems reasonably safe projections given supply contraints are the limitation... - Costs for software development to reduce from $7m to $3m -Converion to software / hardware 50:50 to drive revenue growth - Takeover prospects from HIL put a pretty good security blanket under the price.
And from my perspective the ability to slash admission times by so much gives it a massive unique selling point that will drive mass sales volumes. Hospitals cant resist anything that reduces costs at the same time as increasing beds available. Its an irresistible proposition.
I have family in health and the biggest problems are budget, beds available and waiting for beds to be cleared. This solves all 3 in one hit...
AZV Price at posting:
31.5¢ Sentiment: LT Buy Disclosure: Held